655 related articles for article (PubMed ID: 19789075)
1. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.
Rahn EJ; Hohmann AG
Neurotherapeutics; 2009 Oct; 6(4):713-37. PubMed ID: 19789075
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management.
Shah SA; Gupta AS; Kumar P
J Cancer Res Ther; 2021; 17(1):1-9. PubMed ID: 33723124
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
5. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Aly E; Masocha W
IBRO Neurosci Rep; 2021 Jun; 10():109-118. PubMed ID: 34179865
[TBL] [Abstract][Full Text] [Related]
6. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
7. Peripherally Restricted Cannabinoids for the Treatment of Pain.
Romero-Sandoval EA; Asbill S; Paige CA; Byrd-Glover K
Pharmacotherapy; 2015 Oct; 35(10):917-25. PubMed ID: 26497478
[TBL] [Abstract][Full Text] [Related]
8. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
9. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
Lötsch J; Weyer-Menkhoff I; Tegeder I
Eur J Pain; 2018 Mar; 22(3):471-484. PubMed ID: 29160600
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
[TBL] [Abstract][Full Text] [Related]
12. Recent data on cannabinoids and their pharmacological implications in neuropathic pain.
Coman OA; Paunescu H; Coman L; Badarau A; Fulga I
J Med Life; 2008; 1(4):365-75. PubMed ID: 20108515
[TBL] [Abstract][Full Text] [Related]
13. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids and multiple sclerosis.
Pertwee RG
Mol Neurobiol; 2007 Aug; 36(1):45-59. PubMed ID: 17952649
[TBL] [Abstract][Full Text] [Related]
15. A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.
Nutt DJ; Phillips LD; Barnes MP; Brander B; Curran HV; Fayaz A; Finn DP; Horsted T; Moltke J; Sakal C; Sharon H; O'Sullivan SE; Williams T; Zorn G; Schlag AK
Cannabis Cannabinoid Res; 2022 Aug; 7(4):482-500. PubMed ID: 33998895
[No Abstract] [Full Text] [Related]
16. Cannabinoids for the treatment of neuropathic pain: clinical evidence.
Ashton JC; Milligan ED
Curr Opin Investig Drugs; 2008 Jan; 9(1):65-75. PubMed ID: 18183533
[TBL] [Abstract][Full Text] [Related]
17. Targeting cannabinoid agonists for inflammatory and neuropathic pain.
Cheng Y; Hitchcock SA
Expert Opin Investig Drugs; 2007 Jul; 16(7):951-65. PubMed ID: 17594182
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids and neuropathic pain.
Goya P; Jagerovic N; Hernandez-Folgado L; Martin MI
Mini Rev Med Chem; 2003 Nov; 3(7):765-72. PubMed ID: 14529517
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
Karst M; Wippermann S
Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
